Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

01 Quantum Inc. Interim / Quarterly Report 2023

Mar 21, 2023

44702_rns_2023-03-21_9bffab3a-6bee-4007-9378-a6604a186950.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [199 x 142] intentionally omitted <==

01 Communique Laboratory Inc.

Management’s Discussion and Analysis For the three month periods ended January 31, 2023 and 2022

ONE : TSX-V

Dated: March 20, 2023

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

1. Introduction:

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”) has been prepared by management and is a review of the consolidated operating results and financial position of 01 Communique Laboratory Inc. (“01 Communique” or the “Company”), based upon International Financial Reporting Standards (“IFRS”). This MD&A should be read in conjunction with the Company’s unaudited consolidated financial statements and notes to the audited consolidated financial statements as at and for the three months ended January31, 2023.

The Company maintains appropriate systems of internal control, policies, and procedures that provide management reasonable assurance that assets are safeguarded and that its financial information is reliable.

This document and the related unaudited consolidated financial statements were authorized for issue by the board of directors on March 20, 2023.

All amounts are expressed in Canadian dollars unless otherwise stated. This MD&A is effective as of March 20, 2023.

Additional information on the Company, including its unaudited consolidated financial statements, is filed on SEDAR.

2. Forward-looking Statements:

This MD&A contains certain statements that may constitute “forward-looking” statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forwardlooking statements. Such statements use such words as “may”, “will”, “expect”, “believe”, “plan”, “intend”, “are confident” and other similar terminology. These statements reflect current expectations regarding future events and operating performance and speak only as of the date of this MD&A. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved.

A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, including, but not limited to, risk factors discussed in this MD&A. Although the forward-looking statements contained in this MD&A are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward looking statements. These forward-

1

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

looking statements are made as of the date of this MD&A, and the Company assumes no obligation to update or revise them to reflect new events or circumstances.

3. Corporate Overview:

The Company has two business units. Its primary focus is on its cyber security business unit focusing on post-quantum cybersecurity with the development and commercialization of its IronCAP™ technology. IronCAP™’s patent protected cryptographic system is an advanced Goppa code-based post-quantum cryptographic technology that can be implemented on classical computer systems as we know them today while at the same time can also safeguard against attacks in the future post-quantum world of computing. The Company’s other business unit consists of its remote access business which provides its customers with a suite of secure remote access services and products under its I’m InTouch and I’m OnCall product offerings.

(i) Cyber Security.

There is a new breed of computer in development today called Quantum Computers. A Quantum Computer can process information exponentially faster than “classical computers” which could render existing public key encryption unsecure. Public key encryption is a cornerstone of cyber security today and Quantum Computers may have the ability to hack applications that are based on and using public key encryption. As a result, the Company has devoted a significant amount of time researching this new disruptive cyber security technology and based on this research has proceeded with the development and commercialization of products incorporating our IronCAP™ technology that the Company believes will be secure against Quantum Computer attacks.

The Company believes its IronCAP™ technology has wide ranging applications and is applicable for a number of vertical markets, including but not limited to Virtual Private Networks (VPNs), financial transactions, blockchain networks, cloud storage, development of web sites, password protection and email security. Essentially, whenever data is required to be kept safe from malicious attacks from hackers the Company’s IronCAP™ technology is applicable.

The Company has developed and plans to continue to develop new products based on its IronCAP™ technology. The IronCAP™ Toolkits and IronCAP X™ are the first of these products to be released.

  • (1) IronCAP™ Toolkits are available to vendors and can be used by vendors, for example, to build highly secure “post-quantum” systems for blockchain, 5G/IoT, data storage, remote access/VPN, encryption, digital signing etc. and comply with the PKCS#11, OpenSSL and OpenPGP standards.

2

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

  • (2) IronCAP X, a new cybersecurity product for email/file encryption. This digital signature system is built by implementing the patented technology to provide end-to-end encrypted messages. IronCAP X™ has two major differentiations from what is in the market today. Firstly, offerings in today’s market store users secured emails on email-servers for recipients to read, making email-servers a central target of cyber-attack. IronCAP X™, on the other hand, delivers each encrypted message end-to-end to the recipients such that only the intended recipients can decrypt and read the message. Consumer’s individual messages are protected, eliminating the hackers’ incentive to attack email servers of email providers. Secondly, powered by our patent protected technology, we believe IronCAP X™ is the world’s first quantum-safe, digital signature email system; secured against cyberattacks from today’s systems and from quantum computers in the future. Consumers and businesses using our new cybersecurity product will have tomorrow’s cybersecurity today.

The Company is marketing the IronCAP™ Toolkits and IronCAP X™ through a combination of forging partnerships along the lines of the one for its remote access services and products with Hitachi Business Solution Create Ltd. (“Hitachi Business Solution Create”) to create awareness and grow revenue as well as marketing IronCAP X™ through its web site making the personal use version available free of charge.

There can be no guarantee that either the development of or commercialization of the Company’s IronCAP™ technology will be successful or lead to significant revenues for the Company.

(ii) Remote Access Services and Products.

The Company has developed and markets through its web site a suite of products designed to meet the needs of mobile users who have a requirement for remote access and remote support. These products are marketed under the Company's I'm InTouch and I'm OnCall product lines and are available by a simple download from the Company's web site.

The Company has expended considerable resources in developing and marketing these products. To date these initiatives have not generated sufficient revenue for the Company to become profitable. As the Company moves forward, it plans to maintain its products and make them available from the Company’s web site. There can be no assurance that these initiatives will lead to significant revenues for the Company.

The Company has formed a relationship with Hitachi Solutions Create whereby the companies have co-developed products for the Japanese market based on the Company's intellectual property portfolio. Hitachi Solutions Create retains exclusivity for marketing these products in Japan and the Company retains its marketing rights for the rest of the world.

3

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

There can be no guarantee that this relationship will continue to lead to an increase in revenues for the Company, or that the relationship will lead to other business opportunities which the Company is trying to secure.

4. Intellectual Property:

The Company has been granted a patent in the U.S. and has three U.S., two International PCT and one Japanese patent applications in process for its IronCAP™ technology:

  • United States patent number 11,271,715 for a Cryptographic System and Method. Our invention relates to cryptographic systems and methods. More particularly, our invention relates to public key cryptographic systems and methods that can be used, for example, to build highly secure systems for data storage, access, encryption, decryption, digital signing, and digital signing verification. Our cryptographic system is expected to protect our customers against the everevolving illegitimate and malicious means of gaining access to their data.

  • United States patent application No.16/893,709 for a Cryptographic System and Method that facilitates sending encrypted emails to a recipient. Our invention, as described in the patent application, relates generally to cryptographic systems and methods. In a traditional end-to-end email encryption system, the recipient must first be a user of the system before the sender can send encrypted messages to the recipient. The new method facilitates sending encrypted emails to a recipient without having to first require the recipient to be an existing registered user of IronCAP X. This invention enables a seamless plug-and-play mechanism to automatically invite new IronCAP X users fueling a viral growth pattern.

  • Japanese patent application No. 2020-534078 entitled “A Cryptographic System and Method”.

  • United States patent application No. 17/708,426 and International PCT No. IB-2022053537 for quantum-safe steganography technology which allows covert hiding of sensitive data in any ordinary digital media such as photos and audio/video clips. The ancient application of steganography technology is to “watermark”. 01 has revolutionized this technology for the postquantum era by utilizing the Company’s patent-protected IronCAP™ cryptographic technology. This revolutionary technology can be applied to a broad range of applications including NFTs, digital wallets, digital proof of ownership, etc. An example of practical application is to hide the private key of a digital wallet as a “quantum-safe backup” instead of the current method of generating 24 random words on paper.

  • United States patent application No. 17/972,815 and International PCT No. US22-78536 for blockchain endpoint protection. Quantum security may be enhanced through the use of quantum-safe validators for transactions whereby the quantum-safe validators process quantum-safe addresses and signatures of parties to the transactions. Quantum safety may be added to conventional blockchain transactions, for example, via smart contracts which are executed using cryptographic interlocks to between conventional smart contract execution

4

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

engines and quantum-safe validators to ensure both quantum-safe processing of addresses and signatures and legitimacy of quantum-safe validators in presenting transactions for incorporation on the chain.

The Company has a number of patents and patent applications which are incorporated in its I’m InTouch and I'm OnCall product and service offerings, as follows:

  • United States patent number 6,928,479 (the “ '479 Patent”) entitled "System, computer product and method for providing a private communication portal";

  • United States patent number 6,938,076 entitled "System, computer product and method for interfacing with a private communication portal from a wireless device";

  • United States patent number 8,234,701 entitled "System, method and computer program for remotely sending a digital signal(s) to a computer";

  • Canadian patent number 2,524,039 entitled "System, method and computer program for remotely sending a digital signal(s) to a computer";

  • Canadian patent number 2,309,398, entitled "A system, computer product and method for remotely accessing and controlling a networked computer";

  • Japanese patent number 4,875,094 entitled (as translated) "Method of accessing and/or controlling target computer, involves directing proxy server to send digital signal to target computer, so that remote computer is permitted to access/control target computer on receipt of digital signal";

  • Japanese patent number 5,832,027 entitled (as translated) "Private communication portal provision system for two-way pager network, has location facility computer for facilitating communication between two other computers"

5. First Quarter Fiscal 2023 Highlights:

The Company continued with work to help ensure the successful commercialization of its IronCAP™ technology as well as building revenue from its remote access service business. Going forward the Company plans to continue with its business development efforts forming new partnerships and building on existing partnerships.

The Company has made a significant financial investment to develop its leading-edge post-quantum cryptographic technologies. Unlike its competitors, the Company has created not only the quantumsafe cryptographic engine but also products with recurring revenue and Proof-of-Concepts for its partners such as the patent-pending quantum-safe blockchain, quantum-safe email, and others. With the major part of development efforts on post-quantum cryptography completed, product development will be focused on integrating applications and feature enhancements for the Company’s partners. As such, it is expected research and development expenses will be less than the current level. Moving forward, with recurring revenue in combination with reducing operating expenses, the Company is confident that its cash flow along with its existing cash will be sufficient

5

01 COMMUNIQUE LABORATORY INC. Management Discussion and Analysis (In Canadian dollars) Unaudited

Three month periods ended January 31, 2023 and 2022

to see it through and allow the Company to take advantage of the post-quantum cryptography market potential that is in front of it.

6. Overview of Results of Operations:

The information in the financial table below present selected financial information for the three months ended January 31, 2023 and 2022. Information has been prepared in accordance with IFRS. The amounts are in Canadian Dollars.

Revenue
Expenses:
Selling, general and administrative
Research and development
Withholding taxes
three months ended
31-Jan-23
31-Jan-22
$ 106,803
$ 189,031
199,225
201,502
147,683
175,549
10,250
18,389
357,158
395,440
Loss before other income and expense
Interest income
Interest expense
(250,355)
(206,409)
3,644
186
(797)
(1,418)
Lossforthe period and comprehensiveloss $ (247,508)
$ (207,641)
Loss per common share
Basic
Diluted
Weighted average number of common shares
Basic
Diluted
$ (0.00)
$ (0.00)
$ (0.00)
$ (0.00)
96,101,646
94,451,221
96,101,646
94,451,221

Revenue for the three month period ended January 31, 2023 was $106,803 (2022 - $189,031) a decrease of $82,228. One time development fees were received for enhancements to DoMobile in Japan during the first quarter 2022. These enhancements contributed to an increase in subscriber revenue for 2023, year over year, from the Company’s remote access business which is marketed on a subscription fee basis with recurring royalties.

Stock-based compensation, a non-cash expense, for the three month period ended January 31, 2023 was $59,091 (2022- $46,900) and depreciation also a non-cash expense was $2,522 (2022 - $2,386).

6

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

The loss for the three month period ended January 31, 2023 was $247,508 (2022 - $207,641). The adjusted loss, which excludes stock-based compensation and depreciation which are non-cash expenses, for the first quarter 2023 was $185,895 (2022 - $158,355).

Product development expenses were curtailed towards the end of the quarter as a number of R&D projects were completed which included enhancements to DoMobile, integration of IronCAP™ into the Company’s partners’ HSM, and the integration of IronCAP[TM] into existing public blockchains.

Cash operating expenses for the three month period ended January 31, 2023 which exclude stock based compensation and depreciation were $285,295 (2022 - $327,765) a reduction of $42,470. Going forward, it is anticipated that product development expenses will be less than the current level.

7. Use of Non-IFRS Terms:

  1. In the Company’s financial reporting, reference is made to cash operating expenses, which is a non-IFRS term. This term does not have a standardized meaning under IFRS and therefore it is unlikely it will be comparable to similar measures by other companies. Cash operating expenses are operating expenses (selling, general and administrative expenses plus research and development expenses) excluding the non-cash operating expenses of stock-based compensation, depreciation and amortization. This measure is used to assist in monitoring cash expenses of the Company as it is an indication of the amount of expenses required to fund the Company’s operations on a cash basis. Stock-based compensation is a non-cash expense and is largely dependent on the accounting assumptions and methods used for the calculation. The table below summarizes cash operating expenses.
Total operating expenses
Less - Stock-based compensation
Depreciation of property and equipment
Cash operating expenses
For the three months ended
31-Jan-23
31-Jan-22
$ 346,908
$ 377,051
59,091
46,900
2,522
2,386
$285,295
$ 327,765

Cash operating expenses for the three months ended January 31, 2023 were $285,295 (2022 - $327,765) a decrease of $42,470. Product development expenses were curtailed towards the end of the first quarter 2023 as enhancements to DoMobile were completed along with completed integration of IronCAP™ into the Company’s partners’ HSM.

7

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

  1. In the Company’s financial reporting, reference is made to adjusted loss, which is a non-IFRS term. This term does not have a standardized meaning under IFRS and therefore it is unlikely it will be comparable to similar measures by other companies. The adjusted loss is the loss for the period and comprehensive loss excluding non-cash operating expenses, unusual items and is indicative of the loss for the period excluding non-cash operating expenses which are stock- based compensation, and depreciation and amortization. This measure is used to assist in monitoring cash requirements of the Company as it is an indication of the amount of cash required to fund the Company’s operations, on a cash basis. Stock-based compensation is a non-cash expense and is largely dependent on the accounting assumptions and methods used for the calculation. The table below summarizes the adjusted loss.
Loss for the period and comprehensive loss
Less: non cash operating expenses
Adjusted Loss for the period
For the three months ended
31-Jan-23
31-Jan-22
$ (247,508)
$ (207,641)
61,613
49,286
$ (185,895)
$ (158,355)

The net loss and comprehensive loss for the three months ended January 31, 2023 was $247,508 (2022 – $207,641) includes as part of operating expenses non-cash expenses of $61,613 (2022 - $49,286). Excluding these non-cash operating expenses, which are included in operating expenses, the adjusted loss for 2023 becomes $185,895 (2022 – $158,355) an increase of $17,816.

8. Results of Operations:

Revenue

Revenue attributable to geographical location based on the customer is as follows:

United States
Canada
Asia/Pacific
31-Jan-23
31-Jan-22
$ 1,620
$ 2,590
2,681
2,555
102,502
183,886
$106,803
$189,031

8

01 COMMUNIQUE LABORATORY INC. Management Discussion and Analysis (In Canadian dollars) Unaudited

Three month periods ended January 31, 2023 and 2022

The significant categories of revenue recognized during the periods are as follows:

Royalty and development fees
Subscription fees
For the three months ended
31-Jan-23
31-Jan-22
$ 102,502
$ 183,886
4,301
5,145
$106,803
$189,031

Revenue for the three month period ended January 31, 2023 was $106,803 (2022 - $189,803) a decrease of $82,228. One time development fees were received for enhancements to DoMobile in Japan during the first quarter 2022. These enhancements contributed to an increase in subscriber revenue for 2023, year over year, from the Company’s remote access business which is marketed on a subscription fee basis with recurring royalties.

Gross profit

The vast majority of the Company’s products sold are software based, which typically have a high gross margin. The gross margin for 2023 and 2022 was 100%.

Selling, general and administration (“SG&A”)

Selling, general and administration
Less: stock-based compensation
For the three months ended
31-Jan-23
31-Jan-22
$ 199,225
$ 201,502
(59,091)
(46,900)
$140,134
$154,602

SG&A expenses, net of stock-based compensation for the three months ended January 31, 2023 remained fairly consistent. For the three months ended January 31, 2023 SG&A expenses were $140,134 (2022 - $154,602) a decrease of $14,467.

Stock option expense for the three months ended January 31, 2023 was $59,091 (2022 - $49,600). There were 1,285,000 options granted during the three months ended January 31, 2023 (2022 – Nil). The average grant date fair value of options granted during the three months ended January 31, 2023 was $0.09. The fair value of each option granted has been estimated on the date of grant using the Black-Scholes fair value option-pricing model with the following assumptions used for grants for the three months ended January 31, 2023: expected dividend yield of nil, expected volatility of 110%, weighted average risk-free interest rate of 3% and expected lives of four years. Stock-based compensation includes the expense pertaining to stock options over their vesting period. This includes options granted in the current period as well as prior periods.

9

01 COMMUNIQUE LABORATORY INC. Management Discussion and Analysis (In Canadian dollars) Unaudited

Three month periods ended January 31, 2023 and 2022

Research and development

Research and development For the three months ended
31-Jan-23
31-Jan-22
$ 147,683
$ 175,549

Research and development expenses for the three month period ended January 31, 2023 were $147,683 (2022 - $175,549) a decrease of $27,867. Product development expenses were curtailed towards the end of the quarter as a number of R&D projects were completed which included enhancements to DoMobile, integration of IronCAP™ into the Company’s partners’ HSM, and the integration of IronCAP[TM] into existing public blockchains.

9. Operating Expenses:

The Company presents a functional consolidated statement of operations and comprehensive income in which expenses are aggregated according to the function to which they relate. The Company has identified the major functions as selling, general and administrative expenses; and research and development expenses.

The following tables present the expenses based on their nature:

for the three months ended
31-Jan-23
Selling, general
Research and
and administration
development
Total
Salaries, contractors, commissions
and benefits
Stock-based compensation
Other operating expenses
$ 74,688
$ 122,225
$ 196,913
59,091
-
59,091
65,446
25,458
90,904
$199,225
$147,683
$ 346,908
for the three months ended
31-Jan-22
Selling, general
Research and
and administration
development
Total
Salaries, contractors, commissions
and benefits
Stock-based compensation
Other operating expenses
$ 89,184
$ 148,854
$ 238,038
46,900
-
46,900
65,418
26,695
92,113
$201,502
$175,549
$ 377,051

Operating expenses for the three months ended January 31, 2023 were $346,908 (2022 - $377,051) a decrease of $30,143.

10

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

Salaries, contractors, commissions and benefits for the three months ended January 31, 2023 were $196,913 (2022 - $238,038) a decrease of $41,125 a result of a decrease in personnel related costs in SG&A and research and development as the Company cut back on contractor fees with the completion of product development and marketing projects that were underway.

Other operating expenses required to run the business remained relatively consistent. For the three months ended January 31, 2023 they were $90,904 (2022 - $92,113) a decrease of $1,209.

Stock option expense for the three months ended January 31, 2023 was $59,091 (2022 - $49,600). There were 1,285,000 options granted during the three months ended January 31, 2023 (2022 – Nil). The average grant date fair value of options granted during the three months ended January 31, 2023 was $0.09. The fair value of each option granted has been estimated on the date of grant using the Black-Scholes fair value option-pricing model with the following assumptions used for grants for the three months ended January 31, 2023: expected dividend yield of nil, expected volatility of 110%, weighted average risk-free interest rate of 3% and expected lives of four years. Stock-based compensation includes the expense pertaining to stock options over their vesting period. This includes options granted in the current period as well as prior periods.

10. Liquidity and Capital Resources:

Cash
Guaranteed investment certificate
Combined amounts
As at:
31-Jan-23
31-Oct-22
$ 463,720
$ 487,179
120,000
150,000
$ 583,720
$ 637,179

Combined amounts were $583,720 as at January 31, 2023 (2022 - $637,179) a decrease of $53,459 primarily a result of the following:

  1. The Company funding its adjusted loss of $185,895 which is a use of funds.

  2. A decrease in non-cash working capital of $65,323 a source of funds.

  3. Completion of a private placement providing $67,500 which is a source of funds.

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when due. To the extent that the Company does not believe it has sufficient liquidity to meet these obligations, management will consider securing additional funds through equity or debt transactions.

11

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

However, the Company has sustained substantial losses in recent years and its ability to continue as a going concern is dependent on the Company's ability to generate future profitable operations and cash flows and/or obtain additional financing, which would be contingent upon market and other conditions in the future, which are beyond the Company's control.

At January 31, 2023, the Company had financial assets, consisting of cash, guaranteed investment certificate and accounts receivable of $715,836 (Oct. 31, 2022 - $953,449) and financial liabilities, consisting of accounts payable and accrued liabilities, the Canadian emergency business loan and the lease liability of $239,563 (Oct. 31, 2022 - $379,650).

The Company manages its liquidity risk by continuously monitoring forecasted and actual cash flows.

11. Investment:

The Company made a minority investment in Talent Summit, a private company incorporated in The Bahamas. An amount of $1,500 has been recorded as an asset at the cost paid for the investment. An additional $30,000 is included in prepaid expenses and other assets as a deposit against a future investment in Talent Summit. Management has estimated that the fair value of the investment at January 31, 2023 is unchanged at $1,500.

12. Market Risk:

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk is comprised of currency risk, interest rate risk and market price risk. The Company is exposed to currency risk and interest rate risk.

Currency risk:

Net monetary assets and liabilities due in U.S. dollars include accounts payable of USD 10,621 (Oct. 31, 2022 - USD 21,478) and cash of USD 311,545 (Oct. 31, 2022 – USD 331,564). Net monetary assets due in Japanese Yen include accounts payable of 655,564 Yen (Oct. 31, 2022 - 2,607,152 Yen), $6,507 CAD equivalent, (Oct. 31, 2022 - $23,985) and accounts receivable of 6,555,641 Yen, $65,073 CAD equivalent (October 31, 2022 - 26,071,630 Yen, $239,859 CAD equivalent).

The Company reports its results in Canadian dollars. The Company markets its products in Canada, the United States ("U.S.") and other jurisdictions, including Japan. Sales to Japanese customers are primarily denominated in the Japanese Yen and sales to U.S. and other customers outside Canada in U.S. dollars. Substantially all of the Company's sales are either in U.S. dollars or the Japanese Yen. As a result, the Company is subject to currency risk from sales made and expenses incurred in U.S. dollars and the Japanese Yen. The Company does not hedge the risk related to

12

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

fluctuations in the exchange rate between the U.S. dollar or the Japanese Yen and the Canadian dollar from either the date of the sales transaction to the collection date due or from the date an expense is incurred to the date the payment is made. As at January 31, 2023, the Company had net monetary assets in U.S. dollars of USD 300,924 (Oct. 31, 2022 – USD 310,086) and net monetary assets in the Japanese Yen of 5,900,077 (October 31, 2022 – 23,464,478 Japanese Yen). An increase or decrease in the U.S. to Canadian dollar exchange rate by 10% as at January 31, 2023 would have resulted in a gain in the amount of $41,227 (2022 - $43,800) or a loss of $41,227 (2022 - $43,800), respectively. An increase or decrease in the Japanese Yen to Canadian dollar exchange rate by 10% as at January 31, 2023 would have resulted in a gain in the amount of $5,856 (2022 - nil) or a loss of $5,856 (2022 - nil), respectively.

Interest rate risk:

The Company is exposed to interest rate risk on its fixed rate financial instruments. Fixed rate instruments subject the Company to fair value interest rate risk, as the fair value of the financial instrument fluctuates due to changes in market interest rates. Financial instruments subject to interest rate risk include demand deposits and the liability component of the debenture.

13. Contingencies and Commitments:

The Company is engaged in legal actions from time to time arising in the ordinary course of business. None of these actions, individually or in the aggregate, is expected to have a material adverse effect on the consolidated financial position or results of operations.

In March 2020, the COVID-19 outbreak was declared a global pandemic by the World Health Organization. The situation is dynamic and the ultimate duration and magnitude of the impact on the economy, capital markets and the Company's financial position cannot be reasonably estimated at this time. The Company is monitoring developments and will adapt its business plans accordingly. The actual and threatened spread of COVID-19 globally could adversely impact the Company's operations and ability to raise capital. To date the Company has been able to adapt its operations thereby minimizing the impact from the pandemic.

14. Related Party Transactions:

The remuneration of directors and other key management personnel of the Company during the three month periods ended January 31, 2023 and 2022 was as follows:

2023 2022
Salaries and contractor fees $
69,000
$ 55,000
Stock-based compensation 45,291 6,750
Total $ 114,291 $ 61,750

13

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

The Company's President and Chief Executive Officer (“CEO”) invoices the Company for his services that pertain to research and development pursuant to a contractor agreement. Fees paid under this agreement during 2023 were $24,500 (2022 - $16,500) and have been included in research and development expenses and are included in the salaries and contractor fees amounts in the above table. In addition, the CEO received a salary for 2023 of $21,000 (2022 - $21,000) which has been recorded in selling, general and administrative expenses, and is included in the salaries and contractor fees amounts in the above table.

Salary and contractor fees included in the above table owing to directors and other key management personnel and so included in accounts payable and accrued liabilities at January 31, 2023 is $5,890 (2021 - $7,300). They are unsecured, non-interest bearing with no fixed terms of payment and were paid subsequent to the end of the year.

15. Critical Accounting Estimates:

The preparation of consolidated financial statements prepared in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclose contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the years. Actual results could differ from those estimates. Management must also make estimates and judgements about future results of operations in assessing recoverability of assets and the value of liabilities. These judgements, estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the years in which the estimates are revised and in any future years affected.

Critical judgements and estimates used in the preparation of the consolidated financial statements include the following:

Going concern

The Company’s ability to continue its ongoing and planned software development activities and to continue operations as a going concern is dependent on the Company achieving profitable operations and/or the ability to obtain external financing from time to time.

Income, value added, withholding and other taxes

The Company is subject to income, value added, withholding and other taxes. Significant judgment is required in determining the Company’s provisions for taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognizes liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. The determination of the Company’s income, value added, withholding and other tax liabilities requires interpretation of complex laws and regulations. The

14

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

Company’s interpretation of taxation law as applied to transactions and activities may not coincide with the interpretation of the tax authorities. All tax related filings are subject to government audit and potential reassessment subsequent to the financial statement reporting period. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the tax related accruals and deferred income tax provisions in the period in which such determination is made.

Share-based payments and warrants

Management estimates the values for share-based payments and warrants using market-based valuation techniques. The fair value of the market-based share awards is determined at the date of grant using generally accepted valuation techniques. Assumptions are made and judgment used in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the stock price, expected dividend yield, future employee turnover rates and future employee stock option exercise behaviors and corporate performance. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates.

Development costs qualifying for capitalization

In assessing whether development costs qualify for capitalization, management makes judgments and estimates related to expectations of technical feasibility in completing the project, the probability of future economic benefits, the availability of adequate technical and financial resources to complete the development, the ability to reliably measure the costs, and whether the Company intends to complete development, and to use or sell the assets.

In making these judgments and estimates, management has assessed various sources of information, including but not limited to, criteria for the capitalization of development costs, forecasted cash flows associated with the developments and with operations, in general, which are used to support whether or not the Company will have sufficient resources to complete the development of the assets. Changes in management’s judgments, estimates and assumptions, could have a material effect in the future on the Company’s financial position and results of operations.

Government assistance and investment tax credits

The Company has applied for and received funding from certain government grants and assistance programs. Remaining funding under these grant programs, if any, will be recognized when the Company qualifies and there is reasonable assurance that the grant will be received. Government assistance and investment tax credits received are subject to government audit and potential reassessment subsequent to the reporting period. Where the final outcome of these matters is

15

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

different from the amounts that were initially recorded, such differences will be recognized in operations in the period in which such determination is made.

Revenue recognition

Application of the accounting principles related to the measurement and recognition of revenue requires the Company to make judgments and estimates. Revenue arrangements may be comprised of multiple performance obligations. Judgment is required in determining the performance obligations that exist in an arrangement and the nature of these deliverables.

Discount rate used on leases

The determination of the Company’s lease liabilities and right-of-use assets depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s estimated incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.

16. Risks and Uncertainties:

An investment in Common Shares is speculative and involves a high degree of risk, is subject to the following specific risks, among others, and should be undertaken only by investors whose financial resources are sufficient to enable them to assume such risks. Common Shares should not be purchased by persons who cannot afford the possibility of the loss of their entire investment. Prospective investors should review these risks as well as other matters disclosed elsewhere in this Management Discussion and Analysis with their professional advisors.

Prospects for companies in the computer and software industry generally may be regarded as uncertain given the inherent nature of the industry and, accordingly, investments in such companies should be regarded as speculative.

  • (a) Lack of Revenue and Profitability

The Company has sustained substantial losses and negative cash flows from operations in recent years. The ability to generate future profitable operations and cash flows is dependent on the successful development of and commercialization of the Company’s IronCAP™ technology and/or increased revenues from the Company’s remote access products and services. There can be no guarantee that either the development of or commercialization of the Company’s IronCAP™ technology will be successful or lead to significant revenues for the Company. In addition, there can be no guarantee that the Company’s initiatives with its remote access products and services will lead to significant revenues for the Company. Refer to Section 3. Corporate Overview for the prospects for the Company.

16

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

  • (b) The Future of Quantum Computers

A Quantum Computer can process information exponentially faster than “classical computers” which could render existing public key encryption unsecure. Public key encryption is a cornerstone of cyber security today and Quantum Computers may have the ability to hack applications that are based on and using public key encryption. Quantum Computers are evolving and the timing as to when one will be available that renders public key encryption unsecure is unknown. The Company believes the introduction of such a Quantum Computer will be instrumental for successful commercialization of its IronCAP™ technology and until one is available successful commercialization could be delayed.

In addition, when such a Quantum Computer becomes available and while the Company believes and has designed its IronCAP™ technology to provide a safeguard against malicious attacks by such a Quantum Computer there can be no guarantee such will be the case.

(c) Listing of the Company’s Common Shares

The stock exchange on which the Company's Common Shares currently trade and upon which they may trade in the future have certain minimum listing requirements that must be met in order to be eligible to continue to trade on such exchanges. If the Company is unable to continue to satisfy these criteria it may be delisted from these exchanges and will be required to find a different exchange on which to list. A change in the exchange on which the Common Shares are listed may result in a decreased share price and/or decreased liquidity. Furthermore, if the Company is not able to find a different exchange on which to list shareholders may not be able to transfer their shares. The trading symbol for the Company where the shares are traded in Canada on the TSX-V is ONE and where the shares are traded in the U.S. the symbol is OONEF and the shares are quoted on the OTCQB market.

(d) New Products and Technological Change

The communications software industry is characterized by rapidly changing technology, evolving industry standards and frequent new product introductions, any of which could make the Company's products obsolete. There can be no assurance that the Company will be successful in enhancing existing products or introducing, manufacturing or marketing new products to meet changing end-user requirements and emerging industry standards and protocols. The Company must devote continued efforts and financial resources to develop and enhance existing products and conduct research to develop new products. The development of new, technologically advanced products is a complex and uncertain process requiring high levels of innovation, as well as the accurate anticipation of technological and market trends. The Company may not be able to identify, develop, manufacture, market or support new or enhanced products successfully or on a timely basis and may not be able to respond effectively to product announcements by competitors, technological changes or emerging industry

17

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

standards which could, among other things, have a material adverse effect on the Company's business, operating results or financial condition. The Company may also announce new products or product enhancements, capabilities or technologies that have the potential to replace or shorten the life cycle of its existing product offerings and that may cause customers to defer purchasing its existing products.

(e) Market Acceptance of Products

The Company designs and develops software-based products for the cyber security and the remote access and support markets. As with any technology, there is a substantial risk that the marketplace may not accept the Company's products. Market acceptance of the Company's products depends, in large part, upon its ability to demonstrate its products' performance and cost-effectiveness over competing products and upon the success of its sales efforts as well as those of its customers. The Company may not be able to continue to market its products successfully and no assurance can be given that any of its current or future products will be accepted in the marketplace.

(f) Competition

Competition in the cyber security and the remote access and support markets is intense and growing rapidly. Accordingly, it is possible that new competitors or alliances among competitors and vendors may emerge and rapidly acquire market share. Many of the Company's current and potential competitors have significantly greater financial, technical, marketing, service, support and other resources than the Company, as well as longer operating histories, greater name recognition and larger customer bases. As a result, they may be able to secure resources on more favorable terms than the Company, and they may be able to respond more quickly to changes in customer preferences or to devote greater resources to the development, promotion and sale of their products than can the Company. Increased competition could result in significant price competition, reduced profit margins, fewer customer orders or loss of market share. The Company may not be able to compete successfully with existing or future competitors and cannot ensure that competitive pressures will not materially and adversely affect its business, operating results or financial condition.

(g) No Assurance of Successful Marketing

The Company does not have extensive experience in successfully marketing its products. Thus, there can be no assurance that future efforts to market its products will be successful. If the Company relies on third parties to market its products, the commercial success of such products may be outside of the Company's control.

18

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

(h) Proprietary Technology

The Company's success will depend, in part, on its ability to maintain copyright and trademark protection, trade secret protection and operate without infringing the proprietary rights of third parties. There can be no assurance that the Company's intellectual property rights, copyright and/or trademarks will not be challenged by any third parties, or that the intellectual property rights of others will not have a material adverse effect on the ability of the Company to do business. Furthermore, there can be no assurance that others will not independently develop products similar to those developed by the Company or duplicate any of the Company's products. The Company may be required to obtain licenses for proprietary rights of third parties. No assurance can be given that any licenses required will be available on terms acceptable to the Company. If the Company does not obtain such licenses, it could encounter delays in introducing one or more of its products to the market or could find that the development, manufacture or sale of products requiring such licenses could be precluded. In addition, the Company could incur substantial time, effort and/or costs in policing unauthorized use of its intellectual property and/or in defending itself in suits brought against it or in suits in which the Company attempts to enforce its own intellectual property rights against other parties.

(i) Currency Risk

The Company reports its results in Canadian dollars. The Company markets its products in Canada, the United States ("U.S.") and other jurisdictions, including Japan. Sales to Japanese customers are primarily denominated in the Japanese Yen and sales to U.S. and other customers outside Canada in U.S. dollars. Substantially all of the Company's sales are either in U.S. dollars or the Japanese Yen. As a result, the Company is subject to currency risk from sales made and expenses incurred in U.S. dollars and the Japanese Yen. The Company does not hedge the risk related to fluctuations in the exchange rate between the U.S. dollar or the Japanese Yen and the Canadian dollar from either the date of the sales transaction to the collection date due or from the date an expense is incurred to the date the payment is made.

(j) Product Liability and Insurance

The sale and use of the Company's products or its products under development may entail risk of product liability. Although the Company considers that it currently has adequate insurance coverage for any product liability claim, as the Company expands and introduces new products there can be no assurance that it will be able to obtain appropriate levels of product liability insurance prior to any use of its products. An inability to obtain insurance on commercially reasonable terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by the Company or expose the Company to significant product liability risks. The obligation to pay any product

19

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

liability claim or a recall of a product could have a material adverse effect on the business, financial condition, operating results or prospects of the Company.

  • (k) Dependence on Key Personnel

The Company's ability to develop, manufacture and market its products and compete with current and future competitors depends, to a great extent, on its ability to attract and retain highly qualified personnel (and attract new personnel where required). Competition for such personnel and relationships is intense and the Company must compete in this regard with companies that have substantially greater financial and other resources than it does. The Company is highly dependent on the principal members of its management and research and development staff ("Key Personnel") and, in particular, Mr. Andrew Cheung, its Chief Executive Officer. The loss of Mr. Cheung's services could have the effect of materially impeding the achievement of development objectives. The persons working with the Company are affected by a number of influences outside of the control of the Company. The failure to attract and retain qualified personnel or the loss of the services of one or more Key Personnel could have a material adverse effect on the Company's business, operating results or financial condition.

(l) Public Market and Volatility of Share Price

Factors such as announcements of technological innovation or the introduction of new products by the Company or its competitors, actual or anticipated fluctuations in the Company's operating results, changes in estimates of the Company's future operating results by securities analysts or developments with respect to proprietary rights may have a significant impact on the market price of the Common Shares. In addition, the stock market has experienced volatility which has particularly affected the market prices of equity securities of many high technology companies and which often has been unrelated to the operating performance of such companies. These market fluctuations may materially adversely affect the market price of the Common Shares.

  • (m) Distribution Agreements

The Company's distribution and licensing agreements contain various provisions for termination and/or renewal, some of which provide for termination without cause and on short notice. Such provisions are not uncommon in the industry and the Company anticipates that it will continue to enter into such agreements. Some of the Company's distribution arrangements are also not embodied in written agreements.

  • (n) The Trend towards Industry Consolidation

Consolidation in the software industry continues to occur, with competing companies merging or acquiring other companies in order to capture market share or expand product lines. As this

20

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

consolidation occurs, the nature of the market may change as a result of fewer players dominating particular markets, potentially providing customers with fewer choices. Also, some of these companies offer a broader range of products than the Company, and the Company may not be able to compete effectively against these competitors. Any of these changes may have a significant adverse effect on the future revenues and operating results of the Company.

  • (o) Potential Fluctuations in Quarterly Financial Results

The Company's quarterly financial results could be impacted significantly by the timing of substantial orders and shipments as well as new releases of its products and intellectual property agreements. The Company's operating expenses are based on anticipated revenue levels in the short term, are relatively fixed and are incurred throughout the quarter. Additionally, the Company's products may be subject to long sales cycles. As a result, if expected revenues are not realized as anticipated, the Company's quarterly financial results could be materially adversely affected. Quarterly financial results in the future may be influenced by these or other factors, including possible delays in the shipment of new products and entering into or failing to enter into or renew a material contract or order. Accordingly, there may be significant variations in the Company's quarterly financial results and such results may not meet the expectations of analysts or investors. If this occurs, the price of the Common Shares may decline. See also "Distribution Agreements", "Volatility of Share Price".

  • (p) Control of Shares by Principal Shareholder

Andrew Cheung, the President and Chief Executive Officer of the Company and the principal shareholder of the Company, maintains effective control of the Company through control and/or ownership of, in the aggregate, approximately 12% of the outstanding Common Shares. As a result, Mr. Cheung could exercise significant influence over all matters requiring shareholder approval, including the ability to elect directors and approve fundamental changes to the Company. Such concentration of ownership may have the effect of delaying or preventing a change in control of the Company, its Board or management.

17. Disclosure Controls and Internal Controls over Financial Reporting:

In the course of evaluating its internal controls over financial reporting as at January 31, 2023, management has identified the following material weakness:

There is limited segregation of duties which could result in a material misstatement in the Company’s consolidated interim or annual financial statements. Given the Company’s limited staff level, certain duties within the accounting and finance department cannot be properly segregated. This deficiency, which is pervasive in impact, did not result in a material misstatement to the consolidated financial statements. The Company relies on certain mitigating controls, including periodic substantive review of the consolidated financial statements by the Chief Executive Officer,

21

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

Audit Committee and Board of Directors; however, these mitigating controls do not eliminate the existence of the material weakness.

As at January 31, 2023 the Company’s management evaluated the effectiveness of the design and operation of its disclosure controls and procedures and internal control over financial reporting. Based on their evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that the disclosure controls and procedures and internal control over financial reporting are ineffective as a result of the material weakness in internal control over financial reporting described above.

There have been no significant changes to the Company’s internal control environment during the three months ended January 31, 2023 that would have materially affected the Company’s internal controls over financial reporting.

20. Disclosure of Outstanding Share Data as at March 17, 2023:

The Company’s share capital consists of the following: Authorized:

50,000 Series A preference shares Unlimited preference shares, issuable in series Unlimited common shares

Issued:

96,364,554 common shares

As at March 17, 2023, there were 5,425,000 stock options outstanding convertible into common shares at exercise prices ranging from $0.05 to $0.38. The options expire between June 19, 2023 and January 20, 2027.

The following table summarizes the warrants that are outstanding as at March 17, 2023.

Weighted
average Weighted
remaining average
Number contractual life exercise
Exercise price outstanding (years) price
Warrants issued on private
placement $ 0.35 281,250 1.60 $ 0.35

Each Warrant entitles the holder to acquire one common share of the Company at an exercise price of $0.35 per share until September 6, 2024.

22

Management Discussion and Analysis (In Canadian dollars) Unaudited

01 COMMUNIQUE LABORATORY INC.

Three month periods ended January 31, 2023 and 2022

21. Quarterly Results of Operations:

The following tables sets forth certain information from the unaudited consolidated statements of operation for the eight most recent quarters of operations ended January 31, 2023 as prepared in accordance with IFRS.

for the 3 months ending
Revenue
Expenses:
Selling, general and administrative
Research and development
Withholding taxes
Loss before interest, other income and expense
Foreign exchange gain (loss)
Interest income
Interest expense
Net loss for the period and comprehensive loss
31-Jan-23
31-Oct-22
31-Jul-22
30-Apr-22
$ 106,803
$ 244,183
$ 236,002
$ 357,594
199,225
207,758
221,772
226,782
147,683
255,943
194,132
190,212
10,250
23,985
10,400
22,734
357,158
487,686
426,304
439,728
$ (250,355)
$ (243,503)
$ (190,302)
$ (82,134)
-
61,177
-
-
3,644
2,712
1,125
459
(797)
(1,628)
(1,065)
(1,204)
$ (247,508)
$ (181,242)
$ (190,242)
$ (82,879)
for the 3 months ending 31-Jan-22 31-Oct-21 31-Jul-21 30-Apr-21
Revenue $ 189,031 $ 163,021 $ 211,831 $ 297,231
Expenses:
Selling, general and administrative 201,502 270,627 207,909 194,208
Research and development 175,549 128,348 209,766 138,876
Withholding taxes 18,389 15,807 20,660 29,207
395,440 414,782 438,334 362,291
Loss before interest, other income and expense $ (206,409) $ (251,761) $ (226,503) $ (65,060)
Foreign exchange gain (loss) - (17,554) - -
Interest income 186 215 180 (5)
Interest expense (1,418) (1,468) (1,595) (561)
Government assistance - 20,000 - -
Net loss for the period and comprehensive loss $ (207,641) $ (250,569) $ (227,918) $ (65,626)

23

01 COMMUNIQUE LABORATORY INC.

CORPORATE INFORMATION

DIRECTORS

Andrew Cheung President & CEO

William A. Train Chairman Private investor

Gary Kissack Lawyer, Fogler, Rubinoff LLP

Tyson Macaulay Director

OFFICERS

Andrew Cheung President & CEO

Brian Stringer Chief Financial Officer

Gigi Loo Controller & Corporate Secretary

INVESTOR RELATIONS

e-mail to: [email protected]

CORPORATE HEADQUARTERS

789 Don Mills Road Suite 700 Toronto, Ontario M3C 1T5

Phone: (905) 795-2888 Trading Symbols: Fax: (905) 795-0101 In Canada TSX-V: ONE www.01com.com In U.S. OTCQB: OONEF